NeoGenomics launches PanTracer Pro for advanced-stage solid tumors

NeoGenomics launches PanTracer Pro for advanced-stage solid tumors
NeoGenomics' PanTracer launch

NeoGenomics has announced the launch of PanTracer Pro, a new tool designed to streamline complex molecular testing workflows.

This solution aims to assist clinicians in making informed decisions for patients with advanced-stage solid tumors, addressing a critical need in personalized oncology treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.